COVID-19: pivoting to recovery

As the COVID-19 pandemic continues and the vaccine rollout proceeds at varying paces across the globe, organisations find themselves in different and sometimes multiple stages of the crisis management lifecycle. Using Control Risks’ Readiness, Response and Recovery methodology, we are helping clients navigate their way through the crisis by shaping responses that target rapid commercial recovery and factor in longer-term scenarios. We provide critical insights and advice on how to manage fast-moving information cycles and adapt your existing crisis recovery measures to new developments. Remaining flexible, agile, forward-thinking and empathetic are all essential for a successful outcome.

Recovery

RiskMap 2021: Missing the rebound

: With the arrival of COVID-19 vaccines those businesses that refuse to embrace risk in 2021 are in danger of failing to capitalise on the recovery. Economies most heavily affected by COVID will rebound fastest, with European growth set to outstrip China for the first time in decades. Many businesses will need to transform their business models in even more significant ways than they already have. Companies’ competitiveness will be defined by their values, as much as by productivity and profits.

Recovery

COVID-19 vaccine diplomacy – from nationalism to friendship

Vaccine rollouts have begun quickly in some countries while others wait. We examine the divergent impacts on diplomatic relations between states prioritising domestic vaccination and others sharing their doses overseas.

Recovery

RiskMap2021: A world with long COVID

A year of uneven recovery lies ahead as vaccine rollouts create a world of haves and have nots. Competition will be fierce between nations and within them, and budgets will creak under the weight of their new debt, pushing some countries to the wall, or prolonging austerity. The relationships between state and business and between society and business will be critical for companies. If 2021 does not mark the end of the pandemic, it will be the year that determines what is left when the worst is over.

Recovery

Navigating third-party risks in pharma and life sciences

: Compliance leads at pharmaceutical and life sciences companies have one of the least navigable jobs in our field. The complexity and uncertainty surrounding the COVID-19 pandemic has presented an array of operational issues with third-party compliance.

Response

Rethinking your global corporate response to social unrest

COVID has both intensified and accelerated the threat posed by unrest to business, from both a likelihood and impact standpoint. Key to successfully navigating the way forward is to apply the same holistic, multi-disciplinary approach we advocate for managing all forms of crisis. It’s time to embrace a longer-term view and mindset that acknowledges unrest as the “new norm” – not only in the US, but globally. Read more to uncover the five steps companies can take to prepare for social unrest wherever it occurs.

Recovery

Investing during and after COVID-19

The investment climate created by the COVID-19 pandemic has demanded strong stomachs as fortune has drained from some sectors overnight and seen others flush with opportunity. Political and policy uncertainties, and heightened societal activism, require private market investors to be acutely sensitive to the profile and timing of their investment decisions.

Coverage of COVID-19 on CORE

Existing subscribers to CORE can access regular updates about COVID-19 through the platform. In addition, subscribers can benefit from a direct link to our experts to discuss topics related COVID-19 and their unique circumstances via CORE+ Analyst Access hours.

Login to CORE